Literature DB >> 2138445

Interferon beta augments suppressor cell function in multiple sclerosis.

A Noronha1, A Toscas, M A Jensen.   

Abstract

Suppressor cell function has been previously reported to be decreased in patients with progressive multiple sclerosis (MS). The abnormality could not be corrected in vitro and was present even after patients were treated with immunosuppressive agents. We now report that interferon beta augments suppressor cell function in vitro in progressive MS. Nonspecific suppressor cell function as measured in a concanavalin A (Con A) suppressor assay was reduced in 24 MS patients (mean percent suppression, 19.6 +/- 2.2) when compared to 19 normal subjects (mean percent suppression, 35.0 +/- 3.3). The data are highly significant (p less than 0.001). When recombinant human interferon beta (10(3) units/ml) was added to lymphocyte cultures with Con A, suppressor activity improved significantly. The mean percent suppression improved from 19.6 +/- 2.2 to 37.8 +/- 2.6 in MS (p less than 0.001) and from 35.0 +/- 3.3 to 46.2 +/- 3.5 (p less than 0.025) in control subjects. This study shows that recombinant interferon beta improves suppressor function in humans, an effect that is particularly significant in progressive MS.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2138445     DOI: 10.1002/ana.410270219

Source DB:  PubMed          Journal:  Ann Neurol        ISSN: 0364-5134            Impact factor:   10.422


  15 in total

Review 1.  Mechanisms of action of interferon-beta in multiple sclerosis.

Authors:  B G Arnason; A Dayal; Z X Qu; M A Jensen; K Genç; A T Reder
Journal:  Springer Semin Immunopathol       Date:  1996

Review 2.  Disease-modifying therapies and infectious risks in multiple sclerosis.

Authors:  Alexander Winkelmann; Micha Loebermann; Emil C Reisinger; Hans-Peter Hartung; Uwe K Zettl
Journal:  Nat Rev Neurol       Date:  2016-03-04       Impact factor: 42.937

3.  1H-MRS in patients with multiple sclerosis undergoing treatment with interferon beta-1a: results of a preliminary study.

Authors:  P Sarchielli; O Presciutti; R Tarducci; G Gobbi; A Alberti; G P Pelliccioli; A Orlacchio; V Gallai
Journal:  J Neurol Neurosurg Psychiatry       Date:  1998-02       Impact factor: 10.154

Review 4.  Long-term experience with interferon beta-1b (Betaferon)in multiple sclerosis.

Authors:  Barry G W Arnason
Journal:  J Neurol       Date:  2005-09       Impact factor: 4.849

Review 5.  Immunotherapy for multiple sclerosis.

Authors:  R A Hughes
Journal:  J Neurol Neurosurg Psychiatry       Date:  1994-01       Impact factor: 10.154

6.  Protective effect of transforming growth factor beta 1 on experimental autoimmune diseases in mice.

Authors:  A P Kuruvilla; R Shah; G M Hochwald; H D Liggitt; M A Palladino; G J Thorbecke
Journal:  Proc Natl Acad Sci U S A       Date:  1991-04-01       Impact factor: 11.205

Review 7.  Interferons in relapsing-remitting multiple sclerosis: are there benefits from long-term use?

Authors:  Oscar Fernández
Journal:  CNS Drugs       Date:  2004       Impact factor: 5.749

8.  Intravenous gammaglobulin treatment in multiple sclerosis and experimental autoimmune encephalomyelitis: delineation of usage and mode of action.

Authors:  A Achiron; R Gilad; R Margalit; U Gabbay; I Sarova-Pinhas; I R Cohen; E Melamed; O Lider; S Noy; I Ziv
Journal:  J Neurol Neurosurg Psychiatry       Date:  1994-11       Impact factor: 10.154

Review 9.  Interferons in multiple sclerosis. A review of the evidence.

Authors:  H S Panitch
Journal:  Drugs       Date:  1992-12       Impact factor: 9.546

10.  Review of interferon beta-1b in the treatment of early and relapsing multiple sclerosis.

Authors:  Damiano Paolicelli; Vita Direnzo; Maria Trojano
Journal:  Biologics       Date:  2009-07-13
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.